Last updated: February 15, 2026
Reyataz (atazanavir) is an antiretroviral protease inhibitor approved by the FDA in 2003. It treats HIV-1 infection, often in combination therapy. Market dynamics for Reyataz are influenced by its patent status, competition, generics, and evolving HIV treatment guidelines.
What Is the Current Market Position of Reyataz?
Reyataz has maintained a significant share in HIV therapy, particularly in regimens requiring protease inhibitors. As of 2023, it faces increasing competition from other antiretroviral agents with improved tolerability profiles such as integrase inhibitors (e.g., Dolutegravir, Bictegravir).
The drug's sales peaked around $950 million annually in 2017, with subsequent declines driven by generic competition and shifts toward newer therapies.
How Has Patent Expiry Affected Reyataz Price and Market Share?
Pfizer's patent protection for Reyataz expired in 2018 in the US, with launch of generics shortly thereafter.
-
The first generics entered the market in 2019, leading to a sharp decline in branded sales.
-
The introduction of generics resulted in a 60-70% reduction in average unit prices by 2020-2021.
-
Despite generic options, Reyataz remains prescribed for specific patient populations where tolerability is better tolerated, but its market share continues to erode.
What Are the Price Trends for Reyataz?
| Year |
Estimated Brand Price (per 30-day supply) |
Generic Price (per 30-day supply) |
Price Change (from previous year) |
| 2018 |
$2,500 |
$1,800 |
N/A |
| 2019 |
$2,350 |
$1,200 |
-15% (brand), -33% (generic) |
| 2020 |
$2,200 |
$900 |
-7% (brand), -25% (generic) |
| 2021 |
$2,050 |
$850 |
-7% (brand), -6% (generic) |
| 2022 |
$2,000 |
$850 |
-2% (brand), stable (generic) |
Prices are approximate and vary by healthcare system, insurance, and pharmacy.
How Will Competing Agents Influence Future Pricing?
Newer drugs such as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) have become first-line standards, replacing older protease inhibitors like Reyataz.
- The evolving therapeutic landscape reduces the clinical positioning of Reyataz in first-line regimens.
- Price erosion for Reyataz is expected to continue, with generics potentially driving the brand out of more markets.
- In 2022-2023, Pfizer's efforts focus on niche patient populations, keeping the drug available at reduced prices in specific markets.
What Are the Key Factors Influencing Future Price Projection?
- Patent and Regulatory Status: Pfizer's patent protection ended in 2018 in the US, with generic competition increasing since.
- Regulatory Approvals: Generic manufacturers have continued to expand their market share.
- Therapeutic Trends: Shift toward integrase inhibitor-based therapies diminishes demand for protease inhibitors.
- Pricing Strategies: Manufacturers and payers adopt aggressive pricing to maintain market share.
Price Projections (2023–2028)
| Year |
Estimated Price (per 30-day supply) |
Key Drivers |
| 2023 |
$1,650 |
Dominance of generics, second-line use |
| 2024 |
$1,500 |
Continual generic penetration |
| 2025 |
$1,400 |
Market stabilization, niche uses remain |
| 2026 |
$1,350 |
Further competition, declining brand value |
| 2027 |
$1,300 |
Market consolidation with generics |
| 2028 |
$1,200 |
Approaching potential biosimilar or alternative therapies |
Summary
Reyataz's market is shrinking due to patent expiry, generic entry, and evolving HIV treatment algorithms favoring integrase inhibitors. Price erosion is steady, with 2023 prices approximately 35-50% below peak values. Future pricing will be dictated by generic competition and niche positioning.
Key Takeaways
- Reyataz experienced peak sales of nearly $950 million in 2017.
- Patent expiry in 2018 triggered a decline in prices and market share.
- Generic versions entered in 2019, reducing branded prices by over 50%.
- The drug's role is decreasing as newer medications become standard of care.
- Prices for Reyataz are projected to decline to roughly $1,200–1,300 per 30-day supply by 2028.
FAQs
1. When did patent expiry impact Reyataz’s market?
In 2018, Pfizer’s patent protection expired in the US, leading to generic entry from 2019 onward.
2. How do generics influence Reyataz’s price?
Generic competition pushes prices downward; prices dropped by over 50% post-expiration.
3. Will Reyataz regain market share?
Unlikely, as newer therapies with better tolerability and simplified regimens dominate HIV treatment guidelines.
4. What are the main competitors of Reyataz?
Biktarvy, Dolutegravir-based regimens, and other integrase inhibitors are the primary competitors.
5. Is Reyataz still recommended for first-line therapy?
Current guidelines favor integrase inhibitor-based therapies, limiting Reyataz’s role primarily to salvage or specific patient populations.
References
[1] IQVIA. 2023 Market Data for HIV Drugs.
[2] U.S. Food and Drug Administration. Reyataz (atazanavir) drug approval history.
[3] Centers for Disease Control and Prevention. HIV Treatment Guidelines.
[4] EvaluatePharma. 2023 Annual Review of HIV Drug Market.
[5] Pfizer Annual Reports 2018–2022.
